Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on Jan 09, 2021 12:31pm
296 Views
Post# 32261366

Tinyi Agreement?

Tinyi Agreement?
"Oct 2019 signed binding term sheet with cosmetic distributor Tinyi Trading
Co for distribution rights of TFC 1067 in Asia"

I wonder just how "binding" this agreement is?  You would think there would have been time frames specified within the agreement to reach its conclusion.  With a year and half gone by you'd imagine it would be null and void or at a minimum there would be financial penalties associated for not closing the transaction.  Very well could have been and it just hasn't been disclosed.  In the past things have gone by the wayside and SBM hasn't provide details or spoke of them every again such as the Bloom Burton anti-inflam project. 

Hopefully the SGLT2 Pets news lands soon as that could be a real company maker all on its own.  Couple that with the 4% skin ligtener and SLGT2 clinical trials concluding anytime in Q1 and the first half of 2021 (+ CURE actually promoting these events) could be a real wild ride for SBM.     
<< Previous
Bullboard Posts
Next >>